Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Halozyme Therapeutics (DE:RV7)
FRANKFURT:RV7
Halozyme (RV7) Stock Price & Analysis
2 Followers
RV7 Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€27.43 - €40.59
Previous Close€35.53
Volume0.00
Average Volume (3M)59.00
Market Cap
€4.52B
Enterprise Value€5.62B
Total Cash (Recent Filing)$336.00M
Total Debt (Recent Filing)$1.50B
Price to Earnings (P/E)N/A
Beta0.65
Next Earnings
May 07, 2024EPS Estimate
€0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding126,824,800
10 Day Avg. Volume0
30 Day Avg. Volume59
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)-5.98
Price to Sales (P/S)19.85
Price to Cash Flow (P/CF)11.80
P/FCF Ratio11.60
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.78
Enterprise Value/Gross Profit8.82
Enterprise Value/Ebitda12.41
Forecast
1Y Price Target
€48.20Price Target Upside35.65% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Halozyme News
Bulls Say, Bears Say
Bulls Say
Financial GrowthHalozyme's detailed five-year financial guidance shows significant growth prospects, with projected total revenues reaching $1,565-1,690 million by 2028, underpinned by strong patent protections and a growing portfolio.
Market ExpansionThe Enhanze technology has the potential to capture a substantial share of the $41.7 billion annual U.S. infusion therapy market by converting intravenous drugs to more convenient subcutaneous administrations.
Product DevelopmentThe introduction of a subcutaneous version of OCREVUS with a quick 10-minute injection time could revolutionize treatment by significantly reducing the hours-long infusion time required for the IV formulation.
Bears Say
Commercial RiskRisks include commercial risk with respect to Enhanze, particularly in the multiple myeloma indication.
Financial PerformanceAnalyst lowers 12-month price target to $48 from the prior $61 per share, despite maintaining a Buy rating.
Revenue ForecastProduct Revenue forecasts for the year have been slightly lowered to align with the company's full-year guidance range.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.00% Insiders
0.00% Mutual Funds
0.95% Other Institutional Investors
99.05% Public Companies and
Individual Investors
RV7 FAQ
What was Halozyme Therapeutics’s price range in the past 12 months?
Halozyme Therapeutics lowest stock price was €27.43 and its highest was €40.59 in the past 12 months.
What is Halozyme Therapeutics’s market cap?
Currently, no data Available
When is Halozyme Therapeutics’s upcoming earnings report date?
Halozyme Therapeutics’s upcoming earnings report date is May 07, 2024 which is in 17 days.
How were Halozyme Therapeutics’s earnings last quarter?
Halozyme Therapeutics released its earnings results on Feb 20, 2024. The company reported €0.772 earnings per share for the quarter, beating the consensus estimate of €0.753 by €0.02.
Is Halozyme Therapeutics overvalued?
According to Wall Street analysts Halozyme Therapeutics’s price is currently Undervalued.
Does Halozyme Therapeutics pay dividends?
Halozyme Therapeutics does not currently pay dividends.
What is Halozyme Therapeutics’s EPS estimate?
Halozyme Therapeutics’s EPS estimate is €0.65.
How many shares outstanding does Halozyme Therapeutics have?
Currently, no data Available
What happened to Halozyme Therapeutics’s price movement after its last earnings report?
Halozyme Therapeutics reported an EPS of €0.772 in its last earnings report, beating expectations of €0.753. Following the earnings report the stock price went up 3.762%.
Which hedge fund is a major shareholder of Halozyme Therapeutics?
Among the largest hedge funds holding Halozyme Therapeutics’s share is Driehaus Capital Management LLC. It holds Halozyme Therapeutics’s shares valued at 12M.
---
Halozyme Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€48.20 (35.65% Upside)
€48.20 (35.65% Upside)
Blogger Sentiment
Bullish
DE:RV7 Sentiment 87%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $130.2K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
5.61%
12-Months-Change
Fundamentals
Return on Equity
222.07%
Trailing 12-Months
Asset Growth
-5.88%
Trailing 12-Months
Company Description
Halozyme Therapeutics
Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development & commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.
---
RV7 Company Deck
---
RV7 Earnings Call
Q4 2024
0:00 / 0:00
---
RV7 Revenue Breakdown
54.01% Royalties
36.28% Product sales
9.71% Revenues under collaborative agreements
---
RV7 Stock 12 Months Forecast
Average Price Target
€48.20
▲(35.65% Upside)
Technical Analysis
Best Analysts Covering RV7
1 Year
1 Year Success Rate
7/11 ratings generated profit
1 Year Average Return
+34.73%
reiterated a buy rating 2 months ago
Copying Joseph Catanzaro's trades and holding each position for 1 Year would result in 63.64% of your transactions generating a profit, with an average return of +34.73% per trade.
---